Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | Director · President and CEO | March 16, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date March 16, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,133,777 |
Reported balance
After 2026-03-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-16 · Exercise / conversion · Acquired 15,000 · Balance 2,133,777 F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 2,118,777 |
Reported balance
After 2026-03-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-03-16 · Sale · Disposed 15,000 · Balance 2,118,777 F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025. F2: The price reported in Column 4 is the price at which the shares were sold. |
| Common StockSEC Table I · non-derivative | Direct | 2,112,777 |
Reported balance
After 2026-03-16 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-03-16 · Sale · Disposed 6,000 · Balance 2,112,777 F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025. F2: The price reported in Column 4 is the price at which the shares were sold. F3: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F4: (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F5: (continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.40 · Expires 2034-02-26 | Direct | 690,950 |
Reported balance
After 2026-03-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-16 · Exercise / conversion · Disposed 15,000 · Balance 690,950 F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025. F8: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,143,426 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,143,426 F6: These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 580,957 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 580,957 F7: These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.
F2: The price reported in Column 4 is the price at which the shares were sold.
F3: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
F4: (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
F5: (continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
F6: These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
F7: These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
F8: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2017 Filed Feb 17, 2017 01:10 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001193805-17-000275 · e615799_4-agrossman.xml · derivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2027-02-14 F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 14, 2018, becoming fully vested on February 14, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.